AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection

Published: 16 November 2023

  • Views:

    Views Icon 1814
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family. 


These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

About the episode

AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035). 


This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients with mild to moderate hypertension. 394 participants were enrolled in the trial and were randomised to receive either ALN-AGT01 or placebo. At 6 months, placebo participants were randomized to receive one of the initial ALN-AGT01 regimens until the end of the 12-month treatment period. 

The primary endpoint is the change from baseline at three months in 24-hour mean systolic blood pressure (SBP) assessed by ambulatory blood pressure monitoring (ABPM).


Results suggest that single subcutaneous doses of zilbesiran showed clinically significant reductions in 24-hour mean SBP as compared to placebo at 3 months, which was sustained through to month 6. An encouraging safety profile was demonstrated across this period, with low rates of serious or severe adverse events, and mild to moderate drug-related events observed across all zilbesiran regimens. Study of the drug will continue in the ongoing KARDIA-2 phase 2 study.


Recorded on-site at AHA 2023, Philadelphia.


Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.

Faculty Biographies

George L Bakris

George L Bakris

President Elect

Dr George L. Bakris, MD, is a distinguished member of the National Kidney Foundation's Board of Directors. As the Professor of Medicine and Director of the Comprehensive Hypertension Center at the University of Chicago Medicine, he brings a wealth of expertise to the forefront of medical education.

Previously serving as the Vice-Chairman of Preventive Medicine and Director of the Rush University Hypertension Center in Chicago, Dr Bakris has made significant contributions to the understanding of hypertension, diabetic kidney disease, and nephropathy progression. With a prolific publication record boasting over 700 articles and book chapters, his work has significantly impacted the landscape of cardiovascular research.

Dr Bakris has played a pivotal role in shaping national guidelines, serving on committees such as the Joint National Committee (JNC) Writing Groups VI & 7, the JNC 7 executive committee, the American Diabetes Association Clinical Practice Guideline…

View full profile
Sukriti Banthiya

Sukriti Banthiya

Sukriti was born in India, and graduated from the Medical School in Bangalore, before coming to the US to pursue her Internal Medical Residency at Ascension Providence in Michigan. A visual learner and self-taught artist, she loves to learn using art as an aid to simplify complex concepts in medicine, with a focus on cardiology. She is the author of “Learning Medicine with Art”, a compilation of medical illustrations which aims to make learning fun for the medical student!

View full profile


You must be to comment. If you are not registered, you can register here.